Pharmaceuticals

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.

A quiet South Korean biotech is shaking up the drug delivery landscape. Alteogen's latest deal signals a major shift as Big Pharma races to make treatments better.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

Daniela Cavinatto takes the helm at Haleon Canada, bringing a playbook for transformation to a consumer health giant amid a market booming with new trends.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

Inside the new Louisville hub where automation and an 'end-of-runway' strategy with UPS aim to redefine speed and precision in drug delivery.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

BWXT divests its medical arm to Nordic Capital, refocusing on its nuclear core while the private equity giant doubles down on the booming radiopharma market.

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

Amidst the fallout of its CEO's ouster, Anavex Life Sciences unveils a new board slate to fend off an activist investor's bid for total control.

Curium's landmark $8 billion acquisition of Lantheus is set to create a global powerhouse in nuclear medicine, reshaping patient care and the competitive landscape.